Publications by authors named "Maria Winqvist"

Claim this Profile
D
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
Shuo Ma, Steven T Rosen, Maria Winqvist, Olga Frankfurt, Jane N Winter

Leuk Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Agnes Mattsson, Sandra E Sylvan, Anna Asklid, Joel Wiggh, Maria Winqvist

Br J Haematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy.
Anna Asklid, Sandra Eketorp Sylvan, Agnes Mattsson, Maria Winqvist, Hemming Johansson

Leuk Lymphoma· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Maria Winqvist, Per-Ola Andersson, Anna Asklid, Karin Karlsson, Claes Karlsson

Haematologica· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Maria Winqvist, Marzia Palma, Kia Heimersson, Håkan Mellstedt, Anders Österborg

Br J Haematol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.
Anna Asklid, Maria Winqvist, Sandra Eketorp Sylvan, Agnes Mattsson, Einar Björgvinsson

Leuk Lymphoma· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson

Cancer Immunol Immunother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Maria Winqvist, Anna Asklid, P O Andersson, Karin Karlsson, Claes Karlsson

Haematologica· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis